Pharmacokinetics and Safety of Long‐Acting Testosterone Undecanoate Injections in Hypogonadal Men: An 84‐Week Phase III Clinical Trial

Authors:

Abstract
Currently available testosterone (T) injections in the United States are administered at 2–3 weekly intervals. Less frequent injections with favorable serum T pharmacokinetics would benefit hypogonadal men. The objective of this study is to assess the pharmacokinetics of long‐acting testosterone undecanoate (TU) intramuscular (IM) injection in hypogonadal men. An unblinded, multicenter phase 3 clinical trial was conducted in 31 academic centers and contract research organizations. Males (130) more than 18 years of age with serum total T < 300 ng/dL were enrolled and received 750‐mg injections of TU at weeks 0 and 4 and every 10 weeks thereafter for 9 injections over 84 weeks. The main outcome variables were serum total T, free T, dihydrotestosterone (DHT), estradiol (E2) levels, and safety parameters. After the first injection, patients maintained average trough T concentrations in the adult male range (300–1000 ng/dL or 10.4–34.7 nmol/L) before each injection and at multiple time points measured after the third and fourth injections. Serum free T, DHT, and E2 levels and their ratios to serum T remained relatively consistent once steady state was attained. TU injections were generally well tolerated, with safety profiles similar to other T replacement. We conclude that hypogonadal patients treated for 84 weeks with a 750‐mg IM injection of TU every 10 weeks demonstrated average concentrations of T, its metabolites (DHT and E2), and ratios—DHT:T and E2: T—within the adult male reference range at all time points measured. TU injections would be an acceptable alternative to the currently available 2–3 weekly injectables.

This publication has 25 references indexed in Scilit: